 | • レポートコード：B-MOR-08387 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、神経変性疾患の世界市場について調べ、神経変性疾患の世界規模、市場動向、市場環境、適応症別（パーキンソン病、筋萎縮性側索硬化症、アルツハイマー病、ハンチントン病、その他）分析、薬剤別（N-メチル-D-アスパラギン酸受容体、選択的セロトニン再取り込み阻害剤、ドーパミン抑制剤、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・神経変性疾患の世界市場インサイト ・神経変性疾患の世界市場環境 ・神経変性疾患の世界市場動向 ・神経変性疾患の世界市場規模 ・神経変性疾患の世界市場規模：適応症別（パーキンソン病、筋萎縮性側索硬化症、アルツハイマー病、ハンチントン病、その他） ・神経変性疾患の世界市場規模：薬剤別（N-メチル-D-アスパラギン酸受容体、選択的セロトニン再取り込み阻害剤、ドーパミン抑制剤、その他） ・神経変性疾患の世界市場：地域別市場規模・分析 ・神経変性疾患の北米市場規模・予測 ・神経変性疾患のアメリカ市場規模・予測 ・神経変性疾患のヨーロッパ市場規模・予測 ・神経変性疾患のアジア市場規模・予測 ・神経変性疾患の日本市場規模・予測 ・神経変性疾患の中国市場規模・予測 ・神経変性疾患のインド市場規模・予測 ・神経変性疾患の韓国市場規模・予測 ・関連企業情報・競争状況 |
The neurodegenerative disease market is expected to witness a CAGR of 5.5% during the forecast period, 2018-2023. The market for neurodegenerative disease will experience robust growth, owing to the continuous developments that are made in the medical sector, which is both in the treatment and diagnosis of the neurological disorders.
Increasing Prevalence of Neurodegenerative Disorders
Along with increasing global population and average lifespan, the prevalence of neurological disorders is on the rise, worldwide. The Alzheimer’s Association states that around 5.4 million people in the United States were been living with Alzheimer’s disease, as of 2016. This disease is the sixth leading cause of death in the United States and is more prevalent among people above 65 years of age (5.2 million out of the 5.4 million patients fall in this age bracket). The number is expected to increase during the forecast period, worsening the situation in the coming years. Thus, the prevalence of neurodegenerative disorders is on the rise, contributing to the growth of this market.
The other driving factors include the strong product pipeline for neurodegenerative diseases and new drug launches.
Patent Expiries During the Forecast Period
The neurodegenerative market is facing multiple patent expiries, which are likely to restrain the market globally. Some of the patents include Azilect’s patent expiring in May 2017, Comtan’s patent expiring in 2019, and Stalevo 50 in June 2020. Hence, it is anticipated that the market is going to face a downfall in the coming years. Rilutek, a drug that is used to treat Amyotrophic Lateral Sclerosis, will lose its patent protection in 2018, further reducing the growth of the market. These consecutive patent expiries will enable generics and players, offering low priced products, to enter the market, thus, causing a loss in the revenues for major key players, which is expected to impede the growth of the neurodegenerative market.
The other factors restraining the market include disease complexity and stringent regulations.
North America Dominates the Neurodegenerative Disease Market
With increasing aging population in the United States, a simultaneous increase in neurodegenerative diseases has been observed. Asia-Pacific has also been projected to have the fastest growth, owing to increasing population, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations, such as China, and India, in this region.
Key Developments in the Market
• April 2017: Teva announced FDA approval of AUSTEDO tablets for the treatment of chorea associated with Huntington’s disease
Major Players: NOVARTIS INTERNATIONAL AG, PFIZER INC., MERCK SERONO, BIOGEN IDEC, TEVA PHARMACEUTICAL INDUSTRIES LTD, UCB, BAYER SCHERING, BOEHRINGER INGELHEIM GMBH, SANOFI S.A., AND GLAXOSMITHKLINE PLC. amongst others
Reasons to Purchase the Report
• Current and future neurodegenerative disease market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increased Prevalence of Neurological Disorders
6.1.2 Strong Product Pipeline for Neurodegenerative Diseases
6.1.3 New Drug Launches
6.2 Market Restraints
6.2.1 Patent Expiries During the Forecast Period
6.2.2 Disease Complexity
6.2.3 Stringent Regulations
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Indication Type
7.1.1 Parkinson’s Disease
7.1.2 Amyotrophic Lateral Sclerosis
7.1.3 Alzheimer’s Disease
7.1.4 Huntington Disease
7.1.5 Others
7.2 By Drug Type
7.2.1 N-methyl-D-aspartate receptor
7.2.2 Selective Serotonin Reuptake Inhibitor
7.2.3 Dopamine Inhibitors
7.2.4 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Bayer AG
9.2 Biogen Idec
9.3 Boehringer Ingelheim GmbH
9.4 GlaxoSmithKline plc
9.5 Merck Serono
9.6 Novartis International AG
9.7 Pfizer Inc.
9.8 Sanofi S.A.
9.9 Teva Pharmaceutical Industries Ltd
9.10 List Not Exhaustive
10. Future of the Market